BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q2 2021 vs. Q1 2021
How the institutions holding BIO-TECHNE Corp changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 470 | 3 | 512 | +45 |
| Shares | 36.6M | 396.1K | 36.6M | +381.7K (+1.1%) |
| Value | $14.0B | $151.3M | $16.5B | +$2.65B (+19.2%) |
3 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (85)
Institutions that held BIO-TECHNE Corp at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (40)
Institutions that held BIO-TECHNE Corp at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (3)
Institutions that held BIO-TECHNE Corp at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Waddell & Reed Financial Inc | 324,285 | $123.9M |
| Amundi Asset Management US, Inc. | 70,402 | $26.9M |
| Bokf, NA | 1,400 | $534.0K |